ArticleJournal of gastroenterology2014
Photodynamic therapy for human hepatoma-cell-line tumors utilizing biliary excretion properties of indocyanine green.
Article in Journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Astragaloside IV suppresses migration and invasion of TGF-βNaunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Effect of Combined Perftoran and Indocyanine Green-Photodynamic Therapy on HypoxamiRs and OncomiRs in Lung Cancer Cells.Frontiers in pharmacology · 2022Article
- Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer.International journal of nanomedicine · 2022Review
- Potential of Cyanine Derived Dyes in Photodynamic Therapy.Pharmaceutics · 2021Review
- Near-Infrared Fluorescence Imaging and Photodynamic Therapy for Liver Tumors.Frontiers in oncology · 2021Review
- Application of photodynamic therapy for liver malignancies.Journal of gastrointestinal oncology · 2020Review
- Indocyanine green and its nanosynthetic particles for the diagnosis and treatment of hepatocellular carcinoma.American journal of translational research · 2020Review
- Near-infrared fluorescence imaging and photodynamic therapy with indocyanine green lactosomes has antineoplastic effects for gallbladder cancer.Oncotarget · 2019Article
- A novel liver-specific fluorescent anti-cancer drug delivery system using indocyanine green.Scientific reports · 2019Article
- Leveraging Engineering of Indocyanine Green-Encapsulated Polymeric Nanocomposites for Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2018Review
- Innovative treatment for hepatocellular carcinoma (HCC).Translational gastroenterology and hepatology · 2018Review
- Near-infrared photothermal/photodynamic therapy with indocyanine green induces apoptosis of hepatocellular carcinoma cells through oxidative stress.Scientific reports · 2017Article
- Article
- Evaluation of fluorescence imaging with indocyanine green in hepatocellular carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2016Article
- Article
- Photoacoustic tomography of human hepatic malignancies using intraoperative indocyanine green fluorescence imaging.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhotodynamic therapy (PDT) has not been reported for human hepatoma, because cancer cells only weakly take up the photosensitizer. Indocyanine green (ICG) is a photosensitizer normally excreted into the bile, and bile excretion is impaired in human hepatomas. We examined whether human hepatoma cell lines preferentially take up the ICG and then assessed the effectiveness of PDT using ICG and near-infrared (NIR) laser.
methodsHuH-7 and HepG2 human hepatoma cell lines were transplanted subcutaneously into mice. Developing HuH-7 and HepG2 tumors were confirmed that preferentially took up the ICG in 24 h after ICG was administered to mice via tail vein. The HuH-7 tumor showed a high tumor-to-background fluorescence intensity ratio, 255:1, whereas fluorescence intensity of HuH-7 is increased twofold compared to HepG2. HuH-7 cell transplanted mice were divided into three groups: ICG administration only (ICG+NIR-, n = 8), ICG and NIR laser exposure (ICG+NIR+, n = 12), and NIR laser exposure only (ICG-NIR+, n = 5).
resultsMean tumor volume in the ICG+NIR- and ICG-NIR+ groups increased steadily. In contrast, mean tumor volume in the ICG+NIR+ group did not change between days 0 and 3. Mean tumor volume did not differ significantly between the ICG-NIR+ and ICG-NIR- groups, but was significantly different between the ICG+NIR+ group and both the ICG-NIR+ and ICG+NIR- groups (p < 0.01).
conclusionsICG is preferentially taken up by HuH-7 and HepG2 human hepatoma cell line tumors. The tumor-to-background ratio of HuH-7 tumors, in particular, was extremely high. PDT with NIR laser irradiation suppressed HuH-7 human hepatoma cell line tumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.